ARTICLE | Product Development
Benchmarking lead-212: SSTR2 test kitchen
The clinical data available for lead-212 provides initial proof-of-concept for its efficacy and safety in radioligand therapies for cancer
July 24, 2024 10:08 PM UTC
SSTR2’s popularity as a radioligand target has set the stage for rudimentary benchmarking of next-generation radioisotopes, including lead-212.
Though the validity of head-to-head comparisons is limited by small studies and differences in patient populations, early data on SSTR2-targeting agents in neuroendocrine cancers indicate lead-212 programs could match, and potentially outpace, lutetium-177 and actinium-225 in response rates. ...